<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33586684</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e138634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI138634</ELocationID><ELocationID EIdType="pii" ValidYN="Y">138634</ELocationID><Abstract><AbstractText>Patients with neuromuscular disorders suffer from a lack of treatment options for skeletal muscle weakness and disease comorbidities. Here, we introduce as a potential therapeutic agent a heterodimeric ligand-trapping fusion protein, ActRIIB:ALK4-Fc, which comprises extracellular domains of activin-like kinase 4 (ALK4) and activin receptor type IIB (ActRIIB), a naturally occurring pair of type I and II receptors belonging to the TGF-&#x3b2; superfamily. By surface plasmon resonance (SPR), ActRIIB:ALK4-Fc exhibited a ligand binding profile distinctly different from that of its homodimeric variant ActRIIB-Fc, sequestering ActRIIB ligands known to inhibit muscle growth but not trapping the vascular regulatory ligand bone morphogenetic protein 9 (BMP9). ActRIIB:ALK4-Fc and ActRIIB-Fc administered to mice exerted differential effects - concordant with SPR results - on vessel outgrowth in a retinal explant assay. ActRIIB:ALK4-Fc induced a systemic increase in muscle mass and function in wild-type mice and in murine models of Duchenne muscular dystrophy (DMD), amyotrophic lateral sclerosis (ALS), and disuse atrophy. Importantly, ActRIIB:ALK4-Fc improved neuromuscular junction abnormalities in murine models of DMD and presymptomatic ALS and alleviated acute muscle fibrosis in a DMD model. Furthermore, in combination therapy ActRIIB:ALK4-Fc increased the efficacy of antisense oligonucleotide M12-PMO on dystrophin expression and skeletal muscle endurance in an aged DMD model. ActRIIB:ALK4-Fc shows promise as a therapeutic agent, alone or in combination with dystrophin rescue therapy, to alleviate muscle weakness and comorbidities of neuromuscular disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fredericks</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannell</LastName><ForeName>Marishka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sako</LastName><ForeName>Dianne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenha</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liharska</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Lavanya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloom</LastName><ForeName>Troy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belcheva</LastName><ForeName>Elitza P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Pedro A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castonguay</LastName><ForeName>Roselyne</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keates</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hyunwoo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Asya V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearsall</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suragani</LastName><ForeName>Rajasekhar Nvs</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Acceleron Pharma Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007141">Immunoglobulin Fc Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.30</RegistryNumber><NameOfSubstance UI="D030201">Activin Receptors, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.30</RegistryNumber><NameOfSubstance UI="D030301">Activin Receptors, Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.30</RegistryNumber><NameOfSubstance UI="C498933">Acvr1b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.30</RegistryNumber><NameOfSubstance UI="C425584">activin receptor type II-B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D030201" MajorTopicYN="N">Activin Receptors, Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030301" MajorTopicYN="N">Activin Receptors, Type II</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007141" MajorTopicYN="N">Immunoglobulin Fc Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020966" MajorTopicYN="N">Muscular Disorders, Atrophic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020388" MajorTopicYN="N">Muscular Dystrophy, Duchenne</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug therapy</Keyword><Keyword MajorTopicYN="N">Muscle Biology</Keyword><Keyword MajorTopicYN="N">Neuromuscular disease</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword><Keyword MajorTopicYN="N">Skeletal muscle</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> PO has received compensation from Acceleron Pharma. JL, MF, MC, KW, DS, MCM, RG, KL, LK, TB, EPB, PAM, RC, SK, MJA, AVG, RSP, RK, and RNVSS either are or have been employees of Acceleron Pharma and either own or have owned stock in Acceleron Pharma.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>15</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33586684</ArticleId><ArticleId IdType="pmc">PMC7880416</ArticleId><ArticleId IdType="doi">10.1172/JCI138634</ArticleId><ArticleId IdType="pii">138634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudrappa SS, et al. Human skeletal muscle disuse atrophy: effects on muscle protein synthesis, breakdown, and insulin resistance &#x2014; a qualitative review. Front Physiol. 2016;7:361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997013</ArticleId><ArticleId IdType="pubmed">27610086</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Delafontaine P. Mechanisms of cachexia in chronic disease states. Am J Med Sci. 2015;350(4):250&#x2013;256. doi: 10.1097/MAJ.0000000000000511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0000000000000511</ArticleId><ArticleId IdType="pmc">PMC4587350</ArticleId><ArticleId IdType="pubmed">26083652</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BM. Neuromuscular diseases. Semin Neurol. 2016;36(5):409&#x2013;418. doi: 10.1055/s-0036-1586263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1586263</ArticleId><ArticleId IdType="pubmed">27704495</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JG, Wahl RA. Duchenne and Becker muscular dystrophy in adolescents: current perspectives. Adolesc Health Med Ther. 2018;9:53&#x2013;63. doi: 10.2147/AHMT.S125739.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/AHMT.S125739</ArticleId><ArticleId IdType="pmc">PMC5858539</ArticleId><ArticleId IdType="pubmed">29588625</ArticleId></ArticleIdList></Reference><Reference><Citation>Bladen CL, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4):395&#x2013;402. doi: 10.1002/humu.22758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22758</ArticleId><ArticleId IdType="pmc">PMC4405042</ArticleId><ArticleId IdType="pubmed">25604253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ervasti JM, et al. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345(6273):315&#x2013;319. doi: 10.1038/345315a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/345315a0</ArticleId><ArticleId IdType="pubmed">2188135</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann CJ, et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle. 2011;1(1):21. doi: 10.1186/2044-5040-1-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2044-5040-1-21</ArticleId><ArticleId IdType="pmc">PMC3156644</ArticleId><ArticleId IdType="pubmed">21798099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2011;21(1):47&#x2013;51. doi: 10.1016/j.nmd.2010.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2010.09.006</ArticleId><ArticleId IdType="pubmed">21144751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloss D, et al. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465&#x2013;472. doi: 10.1212/WNL.0000000000002337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002337</ArticleId><ArticleId IdType="pmc">PMC4773944</ArticleId><ArticleId IdType="pubmed">26833937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodino-Klapac LR, et al. Gene therapy for Duchenne muscular dystrophy: expectations and challenges. Arch Neurol. 2007;64(9):1236&#x2013;1241. doi: 10.1001/archneur.64.9.1236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.9.1236</ArticleId><ArticleId IdType="pubmed">17846262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodino-Klapac LR. MicroRNA based treatment of cardiomyopathy: not all dystrophies are created equal. J Am Heart Assoc. 2013;2(4):e000384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828818</ArticleId><ArticleId IdType="pubmed">23969225</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti S, et al. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J. 2013;280(17):4263&#x2013;4280. doi: 10.1111/febs.12178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.12178</ArticleId><ArticleId IdType="pubmed">23387802</ArticleId></ArticleIdList></Reference><Reference><Citation>Charleston JS, et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology. 2018;90(24):e2146&#x2013;e2154. doi: 10.1212/WNL.0000000000005680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005680</ArticleId><ArticleId IdType="pubmed">29752304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon KJ, Blobe GC. Role of transforming growth factor-&#x3b2; superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313409</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A. 1997;94(23):12457&#x2013;12461. doi: 10.1073/pnas.94.23.12457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.23.12457</ArticleId><ArticleId IdType="pmc">PMC24998</ArticleId><ArticleId IdType="pubmed">9356471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010;24(10):1998&#x2013;2008. doi: 10.1210/me.2010-0127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2010-0127</ArticleId><ArticleId IdType="pmc">PMC2954636</ArticleId><ArticleId IdType="pubmed">20810712</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariot V, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8(1):1859. doi: 10.1038/s41467-017-01486-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01486-4</ArticleId><ArticleId IdType="pmc">PMC5709430</ArticleId><ArticleId IdType="pubmed">29192144</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JL, et al. Specific targeting of TGF-&#x3b2; family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci U S A. 2017;114(26):E5266&#x2013;E5275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495232</ArticleId><ArticleId IdType="pubmed">28607086</ArticleId></ArticleIdList></Reference><Reference><Citation>Latres E, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017;8:15153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5414365</ArticleId><ArticleId IdType="pubmed">28452368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol. 2009;296(6):C1248&#x2013;C1257. doi: 10.1152/ajpcell.00104.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00104.2009</ArticleId><ArticleId IdType="pubmed">19357234</ArticleId></ArticleIdList></Reference><Reference><Citation>Aykul S, Martinez-Hackert E. Transforming growth factor-&#x3b2; family ligands can function as antagonists by competing for type II receptor binding. J Biol Chem. 2016;291(20):10792&#x2013;10804. doi: 10.1074/jbc.M115.713487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.713487</ArticleId><ArticleId IdType="pmc">PMC4865925</ArticleId><ArticleId IdType="pubmed">26961869</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458&#x2013;464. doi: 10.1002/mus.25268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25268</ArticleId><ArticleId IdType="pubmed">27462804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako D, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem. 2010;285(27):21037&#x2013;21048. doi: 10.1074/jbc.M110.114959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.114959</ArticleId><ArticleId IdType="pmc">PMC2898293</ArticleId><ArticleId IdType="pubmed">20385559</ArticleId></ArticleIdList></Reference><Reference><Citation>Townson SA, et al. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem. 2012;287(33):27313&#x2013;27325. doi: 10.1074/jbc.M112.377960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.377960</ArticleId><ArticleId IdType="pmc">PMC3431715</ArticleId><ArticleId IdType="pubmed">22718755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntumba K, et al. BMP9/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration. Oncotarget. 2016;7(35):55957&#x2013;55969. doi: 10.18632/oncotarget.11182.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.11182</ArticleId><ArticleId IdType="pmc">PMC5302889</ArticleId><ArticleId IdType="pubmed">27517154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell D, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther. 2010;9(2):379&#x2013;388. doi: 10.1158/1535-7163.MCT-09-0650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-09-0650</ArticleId><ArticleId IdType="pubmed">20124460</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistilli EE, et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol. 2011;178(3):1287&#x2013;1297. doi: 10.1016/j.ajpath.2010.11.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2010.11.071</ArticleId><ArticleId IdType="pmc">PMC3069867</ArticleId><ArticleId IdType="pubmed">21356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Morey-Holton ER, Globus RK. Hindlimb unloading rodent model: technical aspects. J Appl Physiol (1985) 2002;92(4):1367&#x2013;1377. doi: 10.1152/japplphysiol.00969.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00969.2001</ArticleId><ArticleId IdType="pubmed">11895999</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks NE, Myburgh KH. Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways. Front Physiol. 2014;5:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955994</ArticleId><ArticleId IdType="pubmed">24672488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KR, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561&#x2013;571. doi: 10.1002/ana.21338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21338</ArticleId><ArticleId IdType="pubmed">18335515</ArticleId></ArticleIdList></Reference><Reference><Citation>St Andre M, et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017;7(1):25. doi: 10.1186/s13395-017-0141-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13395-017-0141-y</ArticleId><ArticleId IdType="pmc">PMC5679155</ArticleId><ArticleId IdType="pubmed">29121992</ArticleId></ArticleIdList></Reference><Reference><Citation>Morvan F, et al. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc Natl Acad Sci U S A. 2017;114(47):12448&#x2013;12453. doi: 10.1073/pnas.1707925114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1707925114</ArticleId><ArticleId IdType="pmc">PMC5703284</ArticleId><ArticleId IdType="pubmed">29109273</ArticleId></ArticleIdList></Reference><Reference><Citation>Harish P, et al. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD) J Cachexia Sarcopenia Muscle. 2019;10(5):1016&#x2013;1026. doi: 10.1002/jcsm.12438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12438</ArticleId><ArticleId IdType="pmc">PMC6818462</ArticleId><ArticleId IdType="pubmed">31066242</ArticleId></ArticleIdList></Reference><Reference><Citation>McGreevy JW, et al. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8(3):195&#x2013;213. doi: 10.1242/dmm.018424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.018424</ArticleId><ArticleId IdType="pmc">PMC4348559</ArticleId><ArticleId IdType="pubmed">25740330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim CH, et al. The passive mechanical properties of the extensor digitorum longus muscle are compromised in 2- to 20-mo-old mdx mice. J Appl Physiol (1985) 2011;110(6):1656&#x2013;1663. doi: 10.1152/japplphysiol.01425.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.01425.2010</ArticleId><ArticleId IdType="pmc">PMC3119138</ArticleId><ArticleId IdType="pubmed">21415170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaharieva IT, et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy. PLoS One. 2013;8(11):e80263. doi: 10.1371/journal.pone.0080263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080263</ArticleId><ArticleId IdType="pmc">PMC3840009</ArticleId><ArticleId IdType="pubmed">24282529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno H, et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One. 2011;6(3):e18388. doi: 10.1371/journal.pone.0018388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018388</ArticleId><ArticleId IdType="pmc">PMC3068182</ArticleId><ArticleId IdType="pubmed">21479190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorillo AA, et al. TNF-&#x3b1;-induced microRNAs control dystrophin expression in Becker muscular dystrophy. Cell Rep. 2015;12(10):1678&#x2013;1690. doi: 10.1016/j.celrep.2015.07.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.066</ArticleId><ArticleId IdType="pmc">PMC4757433</ArticleId><ArticleId IdType="pubmed">26321630</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingler W, et al. The role of fibrosis in Duchenne muscular dystrophy. Acta Myol. 2012;31(3):184&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631802</ArticleId><ArticleId IdType="pubmed">23620650</ArticleId></ArticleIdList></Reference><Reference><Citation>Desguerre I, et al. A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy. Muscle Nerve. 2012;45(6):803&#x2013;814. doi: 10.1002/mus.23341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23341</ArticleId><ArticleId IdType="pubmed">22581532</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P, et al. Impaired respiratory function in mdx and mdx/utrn(+/-) mice. Muscle Nerve. 2011;43(2):263&#x2013;267. doi: 10.1002/mus.21848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21848</ArticleId><ArticleId IdType="pmc">PMC3103944</ArticleId><ArticleId IdType="pubmed">21254093</ArticleId></ArticleIdList></Reference><Reference><Citation>Coley WD, et al. Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet. 2016;25(1):130&#x2013;145. doi: 10.1093/hmg/ddv460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv460</ArticleId><ArticleId IdType="pmc">PMC4690497</ArticleId><ArticleId IdType="pubmed">26566673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt SJP, et al. Pre- and postsynaptic changes in the neuromuscular junction in dystrophic mice. Front Physiol. 2015;6:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4563167</ArticleId><ArticleId IdType="pubmed">26441672</ArticleId></ArticleIdList></Reference><Reference><Citation>Theroux MC, et al. C Histomorphology of neuromuscular junction in Duchenne muscular dystrophy. Pediatr Anesth. 2008;18(3):256&#x2013;259. doi: 10.1111/j.1460-9592.2008.02411.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9592.2008.02411.x</ArticleId><ArticleId IdType="pubmed">18230070</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pijl EM, et al. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. Eur J Neurosci. 2016;43(12):1623&#x2013;1635. doi: 10.1111/ejn.13249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13249</ArticleId><ArticleId IdType="pubmed">27037492</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol. 2018;80:159&#x2013;188. doi: 10.1146/annurev-physiol-022516-034255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-022516-034255</ArticleId><ArticleId IdType="pubmed">29195055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons PR, Slater CR. Structure and function of the neuromuscular junction in young adult mdx mice. J Neurocytol. 1991;20(12):969&#x2013;981. doi: 10.1007/BF01187915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01187915</ArticleId><ArticleId IdType="pubmed">1686056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt SJP, et al. Recovery of altered neuromuscular junction morphology and muscle function in mdx mice after injury. Cell Mol Life Sci. 2015;72(1):153&#x2013;164. doi: 10.1007/s00018-014-1663-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-014-1663-7</ArticleId><ArticleId IdType="pmc">PMC4282693</ArticleId><ArticleId IdType="pubmed">24947322</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden SJ, et al. Fundamental molecules and mechanisms for forming and maintaining neuromuscular synapses. Int J Mol Sci. 2018;19(2):490. doi: 10.3390/ijms19020490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19020490</ArticleId><ArticleId IdType="pmc">PMC5855712</ArticleId><ArticleId IdType="pubmed">29415504</ArticleId></ArticleIdList></Reference><Reference><Citation>Aartsma-Rus A. Overview on DMD exon skipping. Methods Mol Biol. 2012;867:97&#x2013;116. doi: 10.1007/978-1-61779-767-5_7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-767-5_7</ArticleId><ArticleId IdType="pubmed">22454057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodino-Klapac LR, et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet. 2013;22(24):4929&#x2013;4937. doi: 10.1093/hmg/ddt342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt342</ArticleId><ArticleId IdType="pmc">PMC3895965</ArticleId><ArticleId IdType="pubmed">23863459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu-Nguyen N, et al. Systemic antisense therapeutics for dystrophin and myostatin exon splice modulation improve muscle pathology of adult mdx mice. Mol Ther Nucleic Acids. 2017;6:15&#x2013;28. doi: 10.1016/j.omtn.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2016.11.009</ArticleId><ArticleId IdType="pmc">PMC5363451</ArticleId><ArticleId IdType="pubmed">28325281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, et al. Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. Mol Ther. 2014;22(7):1333&#x2013;1341. doi: 10.1038/mt.2014.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.63</ArticleId><ArticleId IdType="pmc">PMC4088999</ArticleId><ArticleId IdType="pubmed">24732757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mary P, et al. Neuromuscular diseases: diagnosis and management. Orthop Traumatol Surg Res. 2018;104(1S):S89&#x2013;S95.</Citation><ArticleIdList><ArticleId IdType="pubmed">29196274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102(50):18117&#x2013;18122. doi: 10.1073/pnas.0505996102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505996102</ArticleId><ArticleId IdType="pmc">PMC1306793</ArticleId><ArticleId IdType="pubmed">16330774</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori R, et al. BMP signaling controls muscle mass. Nat Genet. 2013;45(11):1309&#x2013;1318. doi: 10.1038/ng.2772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2772</ArticleId><ArticleId IdType="pubmed">24076600</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, et al. Strength and muscle quality in a well-functioning cohort of older adults: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2003;51(3):323&#x2013;330. doi: 10.1046/j.1532-5415.2003.51105.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2003.51105.x</ArticleId><ArticleId IdType="pubmed">12588575</ArticleId></ArticleIdList></Reference><Reference><Citation>Stedman HH, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991;352(6335):536&#x2013;539. doi: 10.1038/352536a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352536a0</ArticleId><ArticleId IdType="pubmed">1865908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo Li Z, et al. Inhibition of myostatin reverses muscle fibrosis through apoptosis. J Cell Sci. 2012;125(Pt 17):3957&#x2013;3965.</Citation><ArticleIdList><ArticleId IdType="pubmed">22685331</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. Am J Pathol. 2011;179(2):915&#x2013;930. doi: 10.1016/j.ajpath.2011.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.04.008</ArticleId><ArticleId IdType="pmc">PMC3157209</ArticleId><ArticleId IdType="pubmed">21689628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo Li Z, et al. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem. 2008;283(28):19371&#x2013;19378. doi: 10.1074/jbc.M802585200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802585200</ArticleId><ArticleId IdType="pmc">PMC2443655</ArticleId><ArticleId IdType="pubmed">18453534</ArticleId></ArticleIdList></Reference><Reference><Citation>de Kretser DM, et al. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol. 2012;359(1-2):101&#x2013;106. doi: 10.1016/j.mce.2011.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2011.10.009</ArticleId><ArticleId IdType="pubmed">22037168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaden BC, et al. Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice. Am J Pathol. 2014;184(4):1152&#x2013;1166. doi: 10.1016/j.ajpath.2013.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2013.12.029</ArticleId><ArticleId IdType="pubmed">24655377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pessina P, et al. Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne muscular dystrophy. Skelet Muscle. 2014;4:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142391</ArticleId><ArticleId IdType="pubmed">25157321</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama K, et al. Hypoxia exaggerates inspiratory accessory muscle deoxygenation during hyperpnoea. Respir Physiol Neurobiol. 2015;211:1&#x2013;8. doi: 10.1016/j.resp.2015.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2015.02.005</ArticleId><ArticleId IdType="pubmed">25747385</ArticleId></ArticleIdList></Reference><Reference><Citation>Slater CR. The structure of human neuromuscular junctions: some unanswered molecular questions. Int J Mol Sci. 2017;18(10):2183. doi: 10.3390/ijms18102183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18102183</ArticleId><ArticleId IdType="pmc">PMC5666864</ArticleId><ArticleId IdType="pubmed">29048368</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal N, Martin PT. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. Dev Neurobiol. 2011;71(11):982&#x2013;1005. doi: 10.1002/dneu.20953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.20953</ArticleId><ArticleId IdType="pmc">PMC3472639</ArticleId><ArticleId IdType="pubmed">21766463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolf R, et al. Degeneration of neuromuscular junction in age and dystrophy. Front Aging Neurosci. 2014;6:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033055</ArticleId><ArticleId IdType="pubmed">24904412</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish LA, Fallon JR. Multiple MuSK signaling pathways and the aging neuromuscular junction. Neurosci Lett. 2020;731:135014.</Citation><ArticleIdList><ArticleId IdType="pubmed">32353380</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt SJP, et al. Effects of in vivo injury on the neuromuscular junction in healthy and dystrophic muscles. J Physiol. 2013;591(2):559&#x2013;570. doi: 10.1113/jphysiol.2012.241679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.241679</ArticleId><ArticleId IdType="pmc">PMC3577526</ArticleId><ArticleId IdType="pubmed">23109110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibebunjo C, et al. Genomic and proteomic profiling reveals reduced mitochondrial function and disruption of the neuromuscular junction driving rat sarcopenia. Mol Cell Biol. 2013;33(2):194&#x2013;212. doi: 10.1128/MCB.01036-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01036-12</ArticleId><ArticleId IdType="pmc">PMC3554128</ArticleId><ArticleId IdType="pubmed">23109432</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe BD, et al. The BMP homolog Gbb provides a retrograde signal that regulates synaptic growth at the Drosophila neuromuscular junction. Neuron. 2003;39(2):241&#x2013;254. doi: 10.1016/S0896-6273(03)00426-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00426-4</ArticleId><ArticleId IdType="pubmed">12873382</ArticleId></ArticleIdList></Reference><Reference><Citation>Baines RA. Synaptic strengthening mediated by bone morphogenetic protein-dependent retrograde signaling in the Drosophila CNS. J Neurosci. 2004;24(31):6904&#x2013;6911. doi: 10.1523/JNEUROSCI.1978-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1978-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729602</ArticleId><ArticleId IdType="pubmed">15295025</ArticleId></ArticleIdList></Reference><Reference><Citation>Berke B, et al. Target-dependent retrograde signaling mediates synaptic plasticity at the Drosophila neuromuscular junction. Dev Neurobiol. 2019;79(11):895&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7397725</ArticleId><ArticleId IdType="pubmed">31950660</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin H, et al. Myostatin-like proteins regulate synaptic function and neuronal morphology. Development. 2017;144(13):2445&#x2013;2455. doi: 10.1242/dev.152975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.152975</ArticleId><ArticleId IdType="pmc">PMC5536874</ArticleId><ArticleId IdType="pubmed">28533206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratacos E, et al. Bone morphogenetic protein-6 is a neurotrophic factor for calbindin-positive striatal neurons. J Neurosci Res. 2002;70(5):638&#x2013;644. doi: 10.1002/jnr.10438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10438</ArticleId><ArticleId IdType="pubmed">12424731</ArticleId></ArticleIdList></Reference><Reference><Citation>Galter D, et al. Differential regulation of distinct phenotypic features of serotonergic neurons by bone morphogenetic proteins. Eur J Neurosci. 1999;11(7):2444&#x2013;2452. doi: 10.1046/j.1460-9568.1999.00667.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.1999.00667.x</ArticleId><ArticleId IdType="pubmed">10383634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordova G, et al. Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front Genet. 2018;9:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902687</ArticleId><ArticleId IdType="pubmed">29692797</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pijl EM, et al. Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. Neuromuscul Disord. 2018;28(5):427&#x2013;442. doi: 10.1016/j.nmd.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2018.02.013</ArticleId><ArticleId IdType="pubmed">29631954</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu-Nguyen N, et al. Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice. Hum Mol Genet. 2019;28(18):3091&#x2013;3100.</Citation><ArticleIdList><ArticleId IdType="pubmed">31179493</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumonceaux J, et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther. 2010;18(5):881&#x2013;887. doi: 10.1038/mt.2009.322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.322</ArticleId><ArticleId IdType="pmc">PMC2890116</ArticleId><ArticleId IdType="pubmed">20104211</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, et al. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Hum Mol Genet. 2016;25(5):964&#x2013;975. doi: 10.1093/hmg/ddv629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv629</ArticleId><ArticleId IdType="pubmed">26758873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose FF, Jr, et al. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2009;18(6):997&#x2013;1005. doi: 10.1093/hmg/ddn426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn426</ArticleId><ArticleId IdType="pmc">PMC2649020</ArticleId><ArticleId IdType="pubmed">19074460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowerman M, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech. 2017;10(8):943&#x2013;954. doi: 10.1242/dmm.030148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.030148</ArticleId><ArticleId IdType="pmc">PMC5560066</ArticleId><ArticleId IdType="pubmed">28768735</ArticleId></ArticleIdList></Reference><Reference><Citation>Apgar JR, et al. Beyond CDR-grafting: structure-guided humanization of framework and CDR regions of an anti-myostatin antibody. MAbs. 2016;8(7):1302&#x2013;1318. doi: 10.1080/19420862.2016.1215786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2016.1215786</ArticleId><ArticleId IdType="pmc">PMC5058614</ArticleId><ArticleId IdType="pubmed">27625211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531&#x2013;543. doi: 10.1016/j.cell.2010.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.07.011</ArticleId><ArticleId IdType="pubmed">20723755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearsall RS, et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep. 2019;9(1):11392. doi: 10.1038/s41598-019-47818-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47818-w</ArticleId><ArticleId IdType="pmc">PMC6684588</ArticleId><ArticleId IdType="pubmed">31388039</ArticleId></ArticleIdList></Reference><Reference><Citation>Percival JM, et al. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol. 2012;228(1):77&#x2013;87. doi: 10.1002/path.4054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4054</ArticleId><ArticleId IdType="pmc">PMC4067455</ArticleId><ArticleId IdType="pubmed">22653783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>